| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. | Blood | 2010 | 4.33 |
| 2 | Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). | Matrix Biol | 2002 | 1.19 |
| 3 | Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. | J Invest Dermatol | 2011 | 0.92 |
| 4 | Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection. | J Pharmacol Exp Ther | 2011 | 0.82 |
| 5 | Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. | J Steroid Biochem Mol Biol | 2002 | 0.81 |